Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: J Surg Res. 2018 Oct 23;234:294–302. doi: 10.1016/j.jss.2018.08.048

Figure 1: GYY4137 improves weight gain and clinical status in WT animals, but not in eNOSKO animals.

Figure 1:

A) The WT NEC group experienced significantly higher percent weight gain than its vehicle control, while this effect was not noted in eNOSKO mice. B) The clinical sickness score was improved in the WT NEC group treated with GYY4137, but this effect was not seen with ablation of eNOS (*: p<0.05 vs. vehicle group).